Latest MDV3100 Stories
TOKYO, March 24, 2014 /PRNewswire/ -- Astellas Pharma Inc.
Breast cancers are defined by their drivers – estrogen and progesterone receptors (ER and PR) and HER2 are the most common, and there are drugs targeting each.
A hormone-depleting drug approved last year for the treatment of metastatic prostate cancer can help eliminate or nearly eliminate tumors in many patients with aggressive cancers that have yet to spread beyond the prostate.
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show.
BOTHELL, Wash. and VANCOUVER, British Columbia, June 6, 2011 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc.
SAN FRANCISCO and TOKYO, Nov. 29, 2010 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
SAN FRANCISCO and TOKYO, Sept. 29 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc.
SAN FRANCISCO, Aug. 9 /PRNewswire-FirstCall/ -- Medivation, Inc.
SAN FRANCISCO, May 10 /PRNewswire-FirstCall/ -- Medivation, Inc.
An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.